Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence

PHASE4CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Urinary Incontinence, Stress
Interventions
DRUG

liposomal bupivacaine

Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.

DRUG

Placebo

Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.

Trial Locations (1)

45220

Cincinnati Urogynecology Associates, Cincinnati

All Listed Sponsors
lead

TriHealth Inc.

OTHER

NCT02296099 - Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence | Biotech Hunter | Biotech Hunter